Clinical trials: Multiple-drug Resistance
HIV Infections
Treatment Intensification for HIV Infected Patients With Multi-Drug Resistant Virus
Drug resistance may develop in HIV infected patients who take anti-HIV drugs, but most patients do well if they continue taking them.
- Trial name
- NCT00102934
- Testing
- Enfuvirtide-intensified HAART
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC
The purpose of this study was to assess the efficacy, safety, tolerability, Pharmacokinetic(s) (PK) and dosimetry of [177Lu]Lu-PSMA-617 when administered in addition to Best Supportive/Best Standard of Care (BSC/BSoC) in Chinese…
- Trial name
- NCT05670106
- Testing
- [177Lu]Lu-PSMA-617, Best supportive/best standard of care (BS/BSOC), 68Ga-PSMA-11
- Where
- 17 sites in China
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
The primary objective of this study is to compare the progression free survival (PFS) of patients with metastatic castration-resistant prostate cancer treated with enzalutamide in combination with LY2157299 (Arm 1) versus…
- Trial name
- NCT02452008
- Testing
- Enzalutamide, LY2157299
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Phase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation.
- Conditions
- Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
- Trial name
- NCT07288359
- Testing
- GVV858, Fulvestrant, Letrozole
- Where
- 16 sites in United States, Canada and 9 more
- Volunteers
- 205 people
- Sponsor
- Novartis Pharmaceuticals
Acute Leukaemia
Amplification and Selection of Antimicrobial Resistance in the Intestine
The worldwide increase in the incidence of multidrug-resistant (MDR) pathogens is alarming. Antimicrobial treatment is a risk factor for the isolation of MDR pathogens and can therefore contribute to the observed trend.
- Trial name
- ASARI (NCT02058888)
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- University Hospital Tuebingen
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors
Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Phase I: Characterize safety and tolerability of ERW316 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation.
- Conditions
- Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Trial name
- NCT07570966
- Testing
- ERW316, Fulvestrant, Letrozole
- Sponsor
- Novartis Pharmaceuticals
HIV Infections
Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance
The goal of this study is to examine whether enfuvirtide (T20, Fuzeon) has continued anti-HIV activity in patients experiencing an incomplete virologic response to an enfuvirtide-based regimen.
- Trial name
- NCT00187551
- Testing
- Interruption of enfuvirtide, enfuvirtide interrupton
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, San Francisco
Tuberculosis
A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.
The purpose of this study is to determine the mycobactericidal activity of combinations of bedaquiline (J), moxifloxacin (M), PA-824 (Pa) and pyrazinamide (Z) regimens during 8 weeks of treatment.
- Trial name
- NC-005 (NCT02193776)
- Testing
- PA-824, bedaquiline, moxifloxacin
- Where
- 10 sites in South Africa, Tanzania and 1 more
- Volunteers
- 240 people
- Sponsor
- Global Alliance for TB Drug Development
Hypertension
DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension
This is a randomized, double-blind, placebo- and active-controlled study of a new experimental drug called darusentan. Darusentan is not currently approved by the United States Food and Drug Administration (FDA), which means that…
- Trial name
- Darusentan (NCT00389779)
- Testing
- Darusentan, Guanfacine
- Where
- 147 sites in United States, Argentina and 8 more
- Volunteers
- 849 people
- Sponsor
- Gilead Sciences
Bacterial Infection, Multiple-drug Resistance
Intravenous Fosfomycin Pharmacokinetics Study
This is a Phase 1, open-label, multiple-dose trial conducted at a single center. The treatment period will consist of three 6 g doses (18 g) of ZTI-01 as a 1-hour intravenous (IV) infusion (+10 minute window).
- Conditions
- Bacterial Infection, Multiple-drug Resistance, Pathogen Resistance
- Trial name
- NCT03910673
- Testing
- Fosfomycin disodium
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
E Coli Infection
Multi-Drug Resistant Organism (MDRO): Study of Highly Resistant Escherichia Coli
This is a prospective, observational, multicenter, case-control study.
- Trial name
- SHREC (NCT04574596)
- Testing
- no Intervention
- Where
- 13 sites in United States
- Volunteers
- 300 people
- Sponsor
- Duke University
Neoplasms, Hodgkin's Disease
Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies
Tapestry Pharmaceuticals, Inc. has developed a novel taxane analog, TPI 287. TPI 287 is synthetically manufactured from naturally occurring taxanes extracted from yew starting material.
- Conditions
- Neoplasms, Hodgkin's Disease, Non-Hodgkin's Lymphoma
- Trial name
- NCT00256191
- Testing
- TPI 287 Injection
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Cortice Biosciences, Inc.
Multidrug Resistant Klebsiella Pneumoniae Infection
Phenotypic and Genotypic Detection of Biofilm Formation and Efflux Pump Activity in Multi-drug Resistant Klebsiella Pneumoniae
1. Sample: urine, pus and sputum samples. 2. Culture: the samples will be inoculated on the MacConkey agar and subcultured on eosine methylene blue agar. 3. Identification of isolates will be done by: Colony morphology.
- Trial name
- Klebsiella (NCT07541690)
- Testing
- Genotypic Detection of Biofilm Formation and Efflux Pump Activity.
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sohag University
Multi-Drug Resistant Organism Colonization
Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)
REACT is a phase two, open-label, randomized, controlled trial of microbiota therapy (MT) to reduce colonization with multi-drug resistant organisms (MDRO).
- Trial name
- NCT06321536
- Testing
- Allogeneic Microbiota in Glycerol (9%) (AMG)
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Emory University
CARRIER STATE
Efficacy of a Probiotic or Fecal Microbiota Transplantation (FMT) on the Eradication of Rectal Multidrug-resistant Gram-negative Bacilli (MDR-GNB) Carriage (PROFTMDECOL)
The working hypothesis is that in patients who are rectal carriers of MDR-GNB (Multi drug-resistant gram negative bacilli), the rate and speed of eradication of the carrier status obtained with NAA regimens are insufficient and…
- Trial name
- PROFTMDECOL (NCT04431934)
- Testing
- PROBIOTIC, FMT REGIMEN
- Where
- Spain
- Volunteers
- 437 people
- Sponsor
- Hospital Clinic of Barcelona
Drug Interactions
Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants
Researchers in this study want to learn how the study drug BAY1817080 interacts with another drug called rosuvastatin (brand name: Crestor) and affects the way the body absorbs, distributes and excretes rosuvastatin in healthy…
- Trial name
- NCT04252300
- Testing
- Rosuvastatin, Rosuvastatin + BAY1817080
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Urinary Tract Infection
Nosocomial Bacteriuria in Geriatric Internal Medicine Services and Follow-up Care and Geriatric Rehabilitation of the Strasbourg University Hospitals
This thesis is a comparative study of the epidemiological characteristics of health-care associated bacteriuria in short and medium term of geriatrics wards in Strasbourg's University Hospital, between 2003 and 2017, in the…
- Trial name
- NCT03577769
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Intra-Abdominal Infections, Skin Disease, Infectious
Tygacil Drug Use Investigation
Secondary Data Collection Study; safety and effectiveness of Tigecycline .under Japanese medical practice
- Trial name
- TIGER (NCT01789905)
- Testing
- Tigecycline (Tygacil)
- Volunteers
- 116 people
- Sponsor
- Pfizer
Lung Cancer, Organoid
Organoids Predict Therapeutic Response in Patients With Multi-line Drug-resistant Lung Cancer
This is a single-center, single-arm, open and exploratory clinical study. The purpose of this study was to evaluate the consistency and accuracy of the organogenic (PDO) model for patients with lung cancer, to predict the…
- Trial name
- NCT05669586
- Testing
- Antitumor therapy guided by organoid drug sensitivity test
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Affiliated Hospital of Jiangnan University
NAsal MEthicillin-resistant Staphylococcus
Prevalence of Multi-Drug Resistant Bacteria in Long-term Care Facilities
Antimicrobial resistance (AMR) is recognized as one of the major threats to global health [1], causing up to 25.000 deaths in the European Union every year, longer hospitalizations and increased healthcare costs.
- Trial name
- PreMDRinLTCF (NCT07234734)
- Where
- Italy
- Volunteers
- 581 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia